Here are Thursday’s biggest calls on Wall Street:
The firm raised its price target on several semis companies on Wednesday evening.
“Raising Ests/PT for NVDA to $205 (prior $192) AMD to $205 (prior $183) as Hyperscaler capex continues to tick higher, while China adds another tailwind. Raise DELL PT to $160 (prior $150) with strong Tier 2 CSP [cloud service providers] ramps. ”
Deutsche said it’s cautiously optimistic on Amazon’s grocery strategy.
“Early yesterday, Amazon announced what it called “one of the most significant grocery expansions” in the company’s history, with free SameDay delivery for US Prime users on perishable orders of $35 or more. While, Amazon’s grocery strategy has been a bit of a moving target, and success has been uneven, we do believe that the new product could prove meaningful to Amazon’s grocery volume in the medium term.”
Citi said the tech giant remains a top idea at the firm.
“MSFT remains a top pick in software, and we believe this week’s announcement is another indication of the company’s strong pricing power, which we believed combined with accelerating cloud/AI share gains can drive outsized returns.”
Bank of America added the stock to its top ideas list.
“We are adding Advanced Micro Devices (AMD) to the US 1 List.”
Citi said it’s sticking with shares of CoreWeave.
“The upcoming lock-up may further pressure shares, but we believe buyers will emerge with continuing strong AI demand and a capacity/revenue inflection in Q4/FY26.”
JPMorgan downgraded the China EV company on rising competition.
“Li Auto (d/g to Neutral): We trim our 2025/26E volume and earnings by ~10-20%, reflecting the fast-changing competitive dynamic facing Li.”
Morgan Stanley raised its price target on the stock to $73 per share from $70 following earnings.
“Cisco’s FQ4 posted upside about in-line with investor expectations, with AI orders accelerating.”
Cantor said shares of the HR software company has an attractive entry point.
“WDAY is a high-quality asset with a strong management team, entrenched competitive position in the enterprise, expanding growth vectors, and latent margin potential. The stock is trading near its all-time low EPS and FCF multiples, which we see as an attractive entry point with a positively skewed risk/reward ratio.”
Wells raised its price target on the stock to $14 per share from $8 and says the solar company remains a top idea.
“We’re raising our PT to $14/sh, based on a DCF framework: $8/sh of base value and $6/sh of terminal value (2030+). ... We continue to view RUN as a top pick in the residential solar space.”
Baird said the drug chain retailer is in the midst of a “healthcare benefits turnaround story.”
“We grow increasingly confident on CVS’ path to unlocking HCB [healthcare benefits] embedded earnings power of ~$5 EPS off 2024.”
The firm said it’s bullish on shares of the biotech company.
“For Regeneron, that cycle has been even more extreme: huge sector outperformance since 2012 until a dramatic reversal over the past year. Time for another look at the company? We think so and launch coverage with a Buy recommendation and a $890 price target.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.